G(i) protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: Implication for intracellular signalization cross-regulation

Molecular Pharmacology

Volumn 55, Issue 3, 1999, Pages 473-480

  Bouaboula, Monsif ^a   Desnoyer, Nathalie ^a   Carayon, Pierre ^a   Combes, Therese ^a   Casellas, Pierre ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID RECEPTOR AGONIST; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; BORDETELLA VIRULENCE FACTOR; BORNANE DERIVATIVE; CANNABINOID RECEPTOR; CELL SURFACE RECEPTOR; DRUG RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHO CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; HAMSTER; HUMAN; METABOLISM; UPREGULATION;

ANIMALS; BORNANES; CHO CELLS; CRICETINAE; GTP-BINDING PROTEINS; HUMANS; PERTUSSIS TOXIN; PYRAZOLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CANNABINOID; RECEPTORS, CELL SURFACE; RECEPTORS, DRUG; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION; VIRULENCE FACTORS, BORDETELLA;

EID: 0032586885     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R and Vogel Z (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905.
2. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP and Allen LF (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature(London) 374:272-276.
3. Bouaboula M, Bourrie B, Rinaldi-Carmona M, Shire D, Le Fur G and Casellas P (1995a) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 270:13973-13980.
4. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Earth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G and Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
5. Bouaboula M, Poinot-Chazel C, Bourne B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G and Casellas P (1995b) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: 637-641.
6. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, Calandra B, Le Fur G and Casellas P (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237:704-711.
7. Braestrup C, Schmiechen R, Neef G, Nielsen M and Petersen EN (1982) Interaction of convulsive ligands with benzodiazepine receptors. Science 216:1241-1243.
8. Chidiac P, Hebert TE, Valiquette M, Dennis M and Bouvier M (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45:490-499.
9. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Nat Acad Sci USA 86: 7321-7325.
10. De Vries L, Elenko E, Hubler L, Jones TL and Farquhar MG (1996) GAIP is membrane-anchored by palmitoylation and interacts with the activated (GTP-bound) form of G alpha i subunits. Proc Nat Acad Sci USA 93:15203-15208.
11. Druey KM, Blumer KJ, Kang VH and Kehrl JH (1996) Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family. J Neurosci 379:742-746.
12. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K Blond O, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
13. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
14. Gil J, Higgins T and Rozengurt E (1991) Mastoparan, a novel mitogen for Swiss 3T3 cells, stimulates pertussis toxin-sensitive arachidonic acid release without inositol phosphate accumulation. J Cell Biol 113:943-950.
15. Glass M and Dragunow M (1995) Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. Neuroreport 6:241-244.
16. Glass M and Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and Dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333.
17. Graham FL and Eb AJ (1973) Transformation of rat cells by DNA of human adenovirus 5. Virology 54:536-539.
18. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
19. Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27:429-436.
20. Kenakin T (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413-463.
21. Kim GD and Milligan G (1994) Receptor availability defines the extent of agonist-mediated G-protein down-regulation in neuroblastoma x glioma hybrid cells transfected to express the beta 2-adrenoceptor. FEBS Lett 355:166-170.
22. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 680:680-685.
23. Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
24. Leyte A, Barr FA, Kehlenbach RH and Huttner WB (1992) Multiple trimeric G-proteins on the trans-Golgi network exert stimulatory and inhibitory effects on secretory vesicle formation. EMBO J 11:4795-4804.
25. Luttrell LM, Van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ (1995) G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J Biol Chem 270:16495-16498.
26. MacEwan DJ and Milligan G (1996) Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists FEBS Lett 399:108-112.
27. Mailleux P, Verslype M, Preud'homme X and Vanderhaeghen JJ (1994) Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain. Neuroreport 5:1265-1268.
28. Matsuda LA, Bonner TI and Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535-550.
29. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. J Neurosci 346:561-564.
30. Milligan G (1993) Agonist regulation of cellular G protein levels and distribution: Mechanisms and functional implications. Trends Pharmacol Sci 44:413-418.
31. i3. J Biol Chem 266:6447-6455.
32. Mullaney I, Carr IC and Milligan G (1996) Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts. Biochem J 315:227-234.
33. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (London) 365:61-65.
34. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrié P, Brelière JC and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
35. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC and Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
36. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P and Le Fur G (1996) Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278:871-878.
37. Roerig SC, Loh HH and Law PY (1992) Identification of three separate guanine nucleotide-binding proteins that interact with the delta-opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells. Mol Pharmacol 41:822-831.
38. 35S]thio)triphosphate binding in rat brain membranes. Life Sci 59:659-668.
39. Van Biesen T, Luttrell LM, Hawes BE and Lefkowitz RJ (1996) Mitogenic signaling via G protein-coupled receptors. Endocr Rev 17:698-714.
40. Weiss JM, Morgan PH, Lutz MW and Kenakin T (1996a) The cubic ternary complex receptor-occupancy model. 1 - Model description. J Theor Biol 178:151-167.
41. Weiss JM, Morgan PH, Lutz MW and Kenakin T (1996b) The cubic ternary complex receptor-occupancy model. 2 - Understanding apparent affinity. J Theor Biol 178:169-182.
42. Wess J (1997) G-protein-coupled receptors: Molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11:346-354.